Mesenchymal stem cells and cardiac repair.
Accumulating clinical and experimental evidence indicates that mesenchymal stem cells (MSCs) are promising cell types in the treatment of cardiac dysfunction. They may trigger production of reparative growth factors, replace damaged cells and create an environment that favours endogenous cardiac repair. However, identifying mechanisms which regulate the role of MSCs in cardiac repair is still at work. To achieve the maximal clinical benefits, ex vivo manipulation can further enhance MSC therapeutic potential. This review focuses on the mechanism of MSCs in cardiac repair, with emphasis on ex vivo manipulation.
Nesselmann
Catharina
C
Department of Cardiac Surgery, University of Rostock, Germany.
Ma
Nan
N
Bieback
Karen
K
Wagner
Wolfgang
W
Ho
Anthony
A
Konttinen
Yrjö T
YT
Zhang
Hao
H
Hinescu
Mihail E
ME
Steinhoff
Gustav
G
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000235:genetics; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D005109:Extracellular Matrix / Q000502:physiology; D005818:Genetic Engineering; D006331:Heart Diseases / Q000628:therapy*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009206:Myocardium / Q000166:cytology*; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D018919:Neovascularization, Physiologic
D019485:Bone Morphogenetic Proteins; D036341:Intercellular Signaling Peptides and Proteins